Blog

22 Sep

Alexander Wu, PhD

March 2, 2024
Posted by Ulisses

Yue Alexander Wu is co-founder and CEO of Cothera Bioscience, Inc., a translation medicine and precision therapeutics company. He was previously President, Chief Executive Officer and Chief Strategy Officer of Crown Bioscience International,...

Jay Chun, MD, PhD

March 2, 2024
Posted by Jitendra

Jay Chun, M.D., Ph.D., has served as the Chief of Neurosurgery and Director of the Atlantic Health Spine Center at Overlook Medical Center at Atlantic Health System since September 2015. Dr. Chun has...

Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications

February 17, 2024
Posted by Jitendra

Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys

February 15, 2024
Posted by Jitendra

14 Sep

Publications

Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

September 14, 2023
Posted by Jitendra

14 Sep

Publications

Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine

September 14, 2023
Posted by Jitendra

05 Jul

Press Release

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based O

July 5, 2023
Posted by Jitendra

16 Jun

Press Release

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX

June 16, 2023
Posted by Jitendra

16 Jun

Publications

Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine

June 16, 2023
Posted by Jitendra

15 Jun

Press Release

Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock

June 15, 2023
Posted by Jitendra

Alexander Wu, PhD

Jay Chun, MD, PhD

Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications

Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys

Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based O

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX

Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine

Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch